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Introduction: We undertook this phase II study to measure post-
operative drug delivery and toxicity of cisplatin plus docetaxel in
patients with resected stage I-III non-small cell lung cancer.
Methods: The primary endpoint was amount of cisplatin delivered
over a planned four cycles of adjuvant chemotherapy. Statistical
design required a cohort to close if the regimen proved unlikely to
improve cisplatin delivery compared with published phase III data.
The first cohort was treated with docetaxel 35 mg/m2 intravenously
(IV) on days 1, 8, and 15, and cisplatin 80 mg/m2 IV on day 15,
every 4 weeks for four planned cycles. A second cohort was treated
with docetaxel 75 mg/m2 IV plus cisplatin 80 mg/m2 IV on day 1
every 3 weeks for four planned cycles.
Results: Sixteen patients were treated with weekly docetaxel and
cisplatin every 4 weeks, with five of 16 (31%) unable to complete
three cycles. Subsequently, 11 patients were treated with docetaxel
and cisplatin every 3 weeks, with six of 11 (55%) unable to complete
three cycles. Among the 11 patients who failed to complete three
cycles, the reasons for stopping included one or more of the
following: fatigue (n  8), nausea (n  4), febrile neutropenia (n 
1), hypotension (n  1), and nephrotoxicity (n  1).
Conclusions: The combination of cisplatin at 80 mg/m2 with do-
cetaxel 35 mg/m2 weekly or 75 mg/m2 every 3 weeks is no better
tolerated than older chemotherapy regimens. The most common
reason to stop chemotherapy was intolerable fatigue. These results
suggest that the most common dose-limiting toxicities are attribut-
able to the cisplatin, given similar problems were encountered
whether the docetaxel was delivered as a single dose every 3 weeks
or as a lower weekly dose.
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(J Thorac Oncol. 2007;2: 638–644)
Cisplatin-based chemotherapy after surgical resection ofstage IB-III non-small cell lung cancer (NSCLC) im-
proves survival over surgery alone. Three recent randomized
studies have demonstrated a reduction in the risk of death of
14% to 30%.1–3 A meta-analysis of five contemporary trials
randomizing over 4500 patients suggested that higher stage
patients derived greater reduction in their risk of death, with
clear benefit in stage II-III disease (hazard ratio [HR] 0.83,
95% confidence interval: 0.73–0.95), and borderline benefit
in IB patients (HR  0.92, 95% confidence interval: 0.78–
1.1).4 The three clinical trials that most clearly demonstrated
this benefit were launched in 1994 to 1995, and the majority
of patients treated in the experimental arm received a com-
bination of cisplatin plus vinorelbine, considered to be the
most effective, least toxic chemotherapy available at the time.
These three trials each planned to deliver four cycles of
chemotherapy over approximately 4 months using a variety
of drugs, doses, and schedules. The International Adjuvant
Lung Trial (IALT) allowed investigators to choose between
cisplatin at 80 mg/m2 intravenously (IV) every 3 weeks
(q3wk), 100 mg/m2 q4wk, or 120 mg/m2 q4wk in combina-
tion with either etoposide 100 mg/m2 IV daily for 3 days per
cycle or vinorelbine 30 mg/m2 IV weekly or vinblastine 4
mg/m2 IV weekly or vindesine 3 mg/m2 IV weekly.2 The
majority of patients received cisplatin with etoposide (56%),
and the second most employed regimen was cisplatin with
vinorelbine (27%). Overall, 74% of patients received 240
mg/m2 total dose of cisplatin in the IALT study. Patients
treated on the ANITA trial (Adjuvant Navelbine International
Trialist Association) received cisplatin 100 mg/m2 IV q4wk
with vinorelbine 30 mg/m2 IV weekly. Sixty-one percent of
patients completed at least three cycles (300 mg/m2 total
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cisplatin dose).3 Patients on the NCIC (National Cancer
Institute of Canada) BR10 trial received cisplatin 50 mg/m2
IV on days 1 and 8, with vinorelbine 25 mg/m2 IV weekly
with 58% of patients completing at least three cycles (300
mg/m2 total cisplatin dose).1 By administering the cisplatin in
this manner, lower rates of grade 3–4 fatigue (15% versus
28%), nausea (10% versus 27%), and treatment-related
deaths (1% versus 2%) were observed compared with
ANITA.1,3 However, this approach did not appear to improve
drug delivery in that similar proportions of patients com-
pleted one, two, three, and four cycles of chemotherapy in
both BR10 and ANITA. The IALT investigators reported the
highest proportion of patients (74%) completing at least three
cycles of adjuvant chemotherapy.
A fundamental principle of adjuvant therapy is that
improving drug delivery, either total dose or dose density,
should improve efficacy. This concept has been shown to be
important to the adjuvant therapy of breast cancer.5 The
IALT, the only individual trial to use a variety of drug
regimens, found no significant interaction between survival
benefit from adjuvant chemotherapy and cisplatin dose (dose
per cycle or total dose) or drug combined with cisplatin
(etoposide or vinca alkaloids).2 This is not surprising given
this was a subgroup analysis in a trial with a small level of
survival benefit.
Using pooled data and meta-analysis, some hypotheses
can be generated regarding drug delivery. A pooled analysis
of all patients randomized to receive adjuvant vinorelbine plus
cisplatin (four trials, n  1888) demonstrated a highly signifi-
cant benefit for this regimen in the adjuvant setting (HR 
0.80, 95% confidence interval: 0.70–0.91, p  0.0007).6 A
larger meta-analysis (five trials, n  4584) allowed compar-
ison of this regimen with other two- and three-drug cisplatin
combinations and demonstrated that cisplatin plus vinorel-
bine was more effective than other drug combinations tested
(HR  0.80 versus 0.93 for other two-drug combinations and
0.98 for other three-drug combinations).4 The authors noted
that the cisplatin plus vinorelbine combination allowed for a
higher total dose of cisplatin to be delivered than the other
combinations, with the majority of patients offered a planned
total dose of as high as 400 mg/m2. Thus, the authors
concluded that the lower benefit with other cisplatin combi-
nations may be due to the lower cisplatin dose.4
Randomized trials in patients with metastatic NSCLC
suggest that cisplatin combinations using third-generation
drugs (docetaxel, gemcitabine, and paclitaxel) may be supe-
rior to older regimens.7–9 These trials lead to U.S. Food and
Drug Administration approval of these new drugs in combi-
nation with cisplatin as first-line chemotherapy for patients
with incurable metastatic NSCLC.
Between 1998 and 2000, a phase III trial was conducted
comparing cisplatin plus vinorelbine with cisplatin plus do-
cetaxel as first-line chemotherapy in more than 800 patients
with metastatic NSCLC.9 In this trial, vinorelbine 25 mg/m2
IV weekly was given with cisplatin 100 mg/m2 IV q4wk.
Docetaxel was delivered at 75 mg/m2 IV with cisplatin 75
mg/m2 IV administered on the same day every 3 weeks. The
results of this trial demonstrated that docetaxel plus cisplatin
was superior to vinorelbine plus cisplatin in terms of radio-
graphic response rate (32% versus 25%, p  0.029), and
overall survival (median survival time, 11.3 versus 10.1
months, p  0.044).9 There were significantly less grade 3–4
nausea, vomiting, and anemia and improved quality of life in
the docetaxel plus cisplatin arm compared with the vinorel-
bine plus cisplatin arm.9 Despite similar proportions of pa-
tients being taken off study for disease progression, patients
in the docetaxel plus cisplatin arm received a higher relative
dose intensity than vinorelbine plus cisplatin (0.94 versus
0.78). These data in metastatic patients suggest that the
combination of cisplatin plus docetaxel might improve drug
delivery and possibly outcomes in the postoperative setting
as well.
Similarly, a 230-patient randomized phase II compari-
son of cisplatin plus vinorelbine with cisplatin plus docetaxel
in patients with metastatic NSCLC documented numerically
superior radiographic response rate, and 2- and 3-year sur-
vival proportion for docetaxel, although the sample sizes
were too small to reach statistical significance. Cisplatin plus
docetaxel also appeared to be safer and better tolerated, with
less febrile neutropenia (10% versus 26%), less treatment-
related mortality (2% versus 8%), fewer instances of dose
delay, and a higher relative dose intensity achieved.10 A
meta-analysis of seven randomized trials (n  2867) com-
paring docetaxel and vinca alkaloids, alone or in combination
with other chemotherapy agents, in the first-line treatment of
metastatic NSCLC demonstrated superior survival with the
use of docetaxel (HR  0.89, 95% confidence interval:
0.82–0.96, p  0.03), along with lower rates of neutropenia
(OR  0.60, 95% confidence interval: 0.39–0.92) and febrile
neutropenia (OR  0.60, 95% confidence interval: 0.39–0.96).11
Based on these data, we hypothesized that a combina-
tion of cisplatin plus docetaxel would be a good alternative to
the chemotherapy used in IALT for the adjuvant treatment of
patients with completely-resected NSCLC. Assessment of
toxicity and drug delivery of cisplatin plus docetaxel in this
study would serve as a prelude to randomized trials compar-
ing docetaxel to vinorelbine in combination with cisplatin
postoperatively. We also hypothesized that cisplatin plus
docetaxel would result in better tolerance of chemotherapy,
and allow for delivery of a higher total dose of cisplatin
compared to published data (IALT). In addition to patient
selection, we were conscious of a number of dependent
variables which could have an impact on cisplatin delivery,
including the dose of cisplatin per cycle, the amount of time
between each dose of cisplatin, the dose of docetaxel deliv-
ered with cisplatin, and the use of ancillary or supportive
medications such as antiemetics or hematopoietic growth
factors. Several randomized studies in patients with meta-
static NSCLC have demonstrated that docetaxel may be
delivered at a lower dose, on a weekly schedule, with lower
rates of fatigue and neutropenia and no apparent loss of
efficacy.12 Furthermore, studies combining gemcitabine with
cisplatin suggest that dose delivery and intensity are best
maintained by delivering cisplatin at the end of the treatment
cycle rather than on day 1.13,14
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PATIENTS AND METHODS
This was an investigator-initiated, two-institution phase
II trial conducted between November 2004 and August 2006
at Memorial Sloan-Kettering Cancer Center, Department of
Medicine, Thoracic Oncology Service in New York, NY, and
Sidney Kimmel Comprehensive Cancer Center at Johns Hop-
kins in Baltimore, MD. The primary efficacy outcome vari-
able was total cisplatin dose delivered.
Our null hypothesis was that docetaxel plus cisplatin
would be no better tolerated than the chemotherapy delivered
in the IALT. In IALT, 74% of patients were able to tolerate
240 mg/m2 of cisplatin. If 75% of patients were able to
tolerate more than three cycles of docetaxel/cisplatin chemo-
therapy, then this regimen would be no better tolerated than
historical chemotherapy. If 90% or more patients completed
all four cycles of docetaxel/cisplatin, then this regimen would
be considered more tolerable. Using a two-stage design, we
planned to enroll 16 patients on each cohort. If 12 patients
tolerated more than three cycles of chemotherapy, then the trial
would be stopped. If 12 patients tolerated more than three
cycles of chemotherapy, the trial would be expanded to 50
patients. If 40 patients tolerated more than three cycles, then
the null hypothesis would be rejected (  10%,   10%).
The first dosing schedule tested delivered docetaxel 35
mg/m2 IV on days 1, 8, and 15, plus cisplatin 80 mg/m2 IV
on day 15, every 4 weeks for a planned four cycles. Eligible
patients were within 2 months of their lung surgery, had
complete resection of stage IB-III NSCLC, had not received
any previous chemotherapy or postoperative radiation ther-
apy, and had adequate hematologic, hepatic, and renal func-
tion. Patients received dexamethasone 8 mg orally the
evening before, morning of, and evening after docetaxel.
Before and after cisplatin, patients received acute and delayed
emesis prophylaxis including a 5-HT3 receptor antagonist
(palonosetron on day 1 or ondansetron, granisetron, or dola-
setron on days 1–3), dexamethasone (12 mg orally (PO) on
days 1–3), and aprepitant (125 mg PO on day 1, 80 mg PO on
days 2 and 3). Patients received standard hydration on days of
cisplatin administration, including instructions to drink 1 to 2
liters of extra fluid the evening before cisplatin, 1 liter of IV
normal saline before cisplatin, an additional liter IV after
cisplatin, and instructions to drink 2 liters of extra fluid
overnight after cisplatin. In the days that followed, patients
were given metoclopramide 10 mg PO every 4 hours, pro-
chlorperazine 10 mg PO every 6 hours, or lorazepam 1 mg
PO every 4 hours as needed for delayed nausea or vomiting.
Prophylactic use of granulocyte growth factors was not per-
mitted. Standardized dose reductions of docetaxel and/or
cisplatin in subsequent cycles were based on observed toxic-
ities. Patients received darbepoetin for chemotherapy-in-
duced anemia if appropriate.
A second cohort tested docetaxel 75 mg/m2 IV plus
cisplatin 80 mg/m2 IV on day 1 every 3 weeks for a planned
four cycles. Due to the higher risk of neutropenia with this
regimen, prophylactic use of hematopoietic growth factors
(pegylated filgrastim) was allowed beginning with cycle 2 if
appropriate.
RESULTS
Between August 2004 and June 2006, 27 patients were
enrolled in this study; 16 received weekly docetaxel and
monthly cisplatin, 11 received docetaxel with cisplatin every
3 weeks. Patient characteristics are summarized in Table 1.
Drug Delivery
Cisplatin delivery and dose limiting toxicities are sum-
marized in Table 2.
The first cohort testing weekly docetaxel was closed
early when only 11 of the first 16 patients (69%) were able to
tolerate 240 mg/m2 of cisplatin, making it statistically
unlikely that this regimen would prove to be better tolerated
than the chemotherapy regimens used in IALT. The most
common dose-limiting toxicity was fatigue, which limited
drug delivery in four of the five patients who dropped out
before receiving 240 mg/m2 of cisplatin. Nephrotoxicity
limited drug delivery in the fifth patient, and one patient was
limited by both fatigue and nausea.
We hypothesized that the fatigue may have been related
to the cumulative effects of two doses of docetaxel on days 1
and 8, leading up to combination of docetaxel and cisplatin
on day 15. Therefore, we amended the protocol to explore the
toxicity of docetaxel plus cisplatin every 3 weeks, which had
the advantage of longer recovery times between cisplatin
doses and fewer treatment days. In this second cohort, only
five of 11 patients treated (45%) were able to tolerate 240
TABLE 1. Patient Characteristics
Weekly
Docetaxel and
Cisplatin (n  16)
Every 3 wk
Docetaxel and
Cisplatin (n  11)
Median age, yr (range) 64 (47–71) 63 (42–71)
Women, no. (%) 8 (50) 6 (55)
Karnofsky performance
status, no. (%)
80% 1 (6) 5 (45)
90% 15 (94) 6 (55)
Type of surgery, no. (%)
Lobectomy 15 (94) 9 (82)
Pneumonectomy 1 (6) 1 (9)
Wedge resection 0 1 (9)
Stage, no. (%)
IB 5 (31) 2 (18)
IIA 3 (19) 2 (18)
IIB 1 (6) 4 (37)
IIIA 5 (31) 1 (9)
IIIB 2 (13) 2 (18)
Histology, no. (%)
Adenocarcinoma 8 (50) 8 (73)
Squamous carcinoma 2 (13) 2 (18)
Adenosquamous 3 (19) 1 (9)
Large cell 1 (6) 0
Poorly differentiated 1 (6) 0
Bronchioloalveolar 1 (6) 0
Days from surgery to 1st
chemotherapy (range)
50 (22–55) 50 (40–79)
Azzoli et al. Journal of Thoracic Oncology • Volume 2, Number 7, July 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer640
mg/m2 of cisplatin, and this cohort was also closed to accrual.
Once again, the most common dose-limiting toxicity was
fatigue, which limited drug delivery in four of the six patients
who dropped out. Other dose-limiting toxicities included
nausea (n 1) and febrile neutropenia with hypotension (n
1). Two patients were limited by both fatigue and nausea.
The median cisplatin delivery was 240 mg/m2 in both
cohorts (range, 80–380 mg/m2). Of note, patients who re-
ceived weekly docetaxel and monthly cisplatin received more
docetaxel and completed their chemotherapy in 16 weeks.
Patients who received docetaxel and cisplatin every 3
weeks received less docetaxel, but completed their chemo-
therapy in 12 weeks, thereby achieving a higher dose
density of cisplatin.
Toxicity
There were no treatment-related deaths. Twelve of 27
patients (44%) experienced a serious adverse event related to
study treatment, including admissions to the hospital for
nausea requiring intravenous fluids (n  5), pleural effusion
(n  2), supraventricular tachycardia (n  2), febrile neutro-
penia (n  1), diarrhea (n  1), and hypersensitivity (n  1).
Observed grade 3–4 toxicities are summarized in Table 3. In
both cohorts, the most common reason for stopping adjuvant
therapy was intolerable fatigue, which typically occurred
after the first cycle of chemotherapy.
Efficacy
Twenty-seven patients have been treated with adjuvant
cisplatin plus docetaxel, with a median follow-up of 18
months (range, 4–26). As of August, 2006, two patients have
died, both due to recurrent NSCLC (stages IIIA and IIIB).
Three other patients (stages IIIA, IIA, IB) have experienced
recurrence of NSCLC and remain alive. Median disease- free
and overall survival times have not been reached.
DISCUSSION
Based on available data, cisplatin plus vinorelbine is
the best and most studied drug regimen for adjuvant treatment
of NSCLC. Randomized trials to establish alternative or
superior chemotherapy will require large sample sizes and
years of follow-up. Meanwhile, the list of promising drugs for
the treatment of metastatic NSCLC continues to grow.
In 1994, vinorelbine was approved by the U.S. Food
and Drug Administration (FDA) for the treatment of meta-
static NSCLC, both as a single agent and in combination with
cisplatin. Since the positive adjuvant trials were launched in
1995, there have been three additional drugs approved by the
FDA in combination with cisplatin for first-line therapy of
metastatic NSCLC (paclitaxel, gemcitabine, and docetaxel).
There are also drugs in common use based on phase III
efficacy (most notably carboplatin), which have not been
FDA approved. Many phase III comparisons of two-drug,
cytotoxic combinations in patients with metastatic NSCLC
have shown relative equivalence in efficacy among cisplatin-
based, carboplatin-based, and nonplatinum combinations.9,15–18
Recent meta-analyses suggest that cisplatin combinations are
superior to carboplatin combinations in terms of response rate
and survival.19,20 These data suggest that cisplatin should be
included as part of a planned adjuvant regimen.
There are three drugs that have been shown to improve
survival as single-agents in second-line therapy for metastatic
NSCLC: docetaxel, erlotinib, and pemetrexed. To date, only
one targeted therapy, the anti–vascular endothelial growth
factor agent bevacizumab, has improved survival for selected
patients with metastatic NSCLC when given in combination
with chemotherapy compared with chemotherapy alone.21
The efficacy of bevacizumab in the adjuvant setting will be
examined in the upcoming intergroup randomized adjuvant
trial, Eastern Cooperative Oncology Group (ECOG) 1505.22
In addition to bevacizumab, numerous other molecularly
targeted drugs with demonstrated activity in metastatic
NSCLC are on the horizon.
Given the pace with which new drugs are being devel-
oped, it is difficult or impossible to test them all in the
adjuvant setting. ECOG has gone so far as to intuitively adopt
regimens for adjuvant therapy based on data in metastatic
patients. The treatment regimens for the ECOG 1505 inter-
group adjuvant trial are docetaxel/cisplatin, gemcitabine/cis-
platin, and vinorelbine/cisplatin, all given alone or in combi-
nation with bevacizumab.22 These regimens were adopted
based on efficacy data in the metastatic setting and to allow
for a variety of regimens to enhance accrual to the trial. A
carboplatin-based regimen was not included given meta-








240 3 Fatigue (2), neuropathy (1), diarrhea (1),
disease progression (1)
81–220 3 Fatigue (2), nephrotoxicity (1), nausea (1)




240 1 Nausea (1)
81–220 2 Fatigue (1), nausea (1)
80 4 Fatigue (3), nausea (2), febrile neutropenia
(1), hypotension (1)
a Some patients experienced more than one dose-limiting toxicity or event.
TABLE 3. Observed Grade 3–4 Toxicity
Weekly
Docetaxel and
Cisplatin (n  16)
Every 3 wk
Docetaxel and
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analyses of trials in metastatic NSCLC, suggesting inferiority
compared with cisplatin and the lack of positive clinical trial
data using anything but cisplatin combinations in the adjuvant
setting.23 At this time, carboplatin should not be routinely
recommended as part of an adjuvant regimen.
The adoption of regimens for use in the adjuvant setting
in the absence of data is innovative and unfounded. There are
examples in other disease types in which chemotherapy
regimens of superior efficacy in the metastatic setting proved
to be no better or even harmful in the adjuvant setting. For
example, novel combinations of fluorouracil and irinotecan,
which have been shown to be superior to fluorouracil alone
for the treatment of metastatic colon cancer,24 repeatedly
failed in the adjuvant setting due to increased toxicity and
lack of clinical benefit.25–27 Similarly, there are data that
suggest that docetaxel is superior to paclitaxel for metastatic
breast cancer28; however, paclitaxel and docetaxel have
equivalent efficacy, with higher toxicity for docetaxel when
given after doxorubicin and cyclophosphamide in the adju-
vant treatment of breast cancer.29 Conversely, novel combi-
nations of docetaxel and cyclophosphamide are less toxic and
more effective than doxorubicin and cyclophosphamide in the
adjuvant setting.30
The design of our trial rested on the assumption that
drug delivery is an important determinant of the effectiveness
of adjuvant chemotherapy for NSCLC and that drug delivery
is a reasonable endpoint for a phase II tolerability study. The
results of a randomized trial comparing docetaxel/cisplatin
with vinorelbine/cisplatin in patients with metastatic NSCLC
suggested that the combination docetaxel/cisplatin was supe-
rior in terms of drug delivery, response rate, and survival.9
The median number of treatment cycles delivered was five
over 15 weeks for docetaxel/cisplatin and four over 16 weeks
for vinorelbine/cisplatin, with a lower relative dose intensity
for vinorelbine/cisplatin (0.94 versus 0.78). Similar propor-
tions of patients were taken off study for disease progression
(30% in both arms). These data are corroborated by random-
ized phase II data showing similar trends in drug delivery,
response rate, and survival between these two regimens.10
However, patients with NSCLC who have recently under-
gone surgery are clearly a different population than patients
with metastatic NSCLC and may exhibit a different tolerance
and side effect profile.
This is the first clinical trial to test the tolerability of
docetaxel/cisplatin in the adjuvant setting. Our trial was
designed to demonstrate that docetaxel/cisplatin delivered to
patients with completely resected NSCLC allowed a higher
total dose of cisplatin than with the chemotherapy regimens
used in IALT (including cisplatin combined with etoposide,
vinorelbine, vindesine, and vinblastine). As a result of early
closure due to poor drug delivery, the sample size of this trial
is small (n  27). Nevertheless, conclusions can be drawn
regarding dose-limiting toxicities, which have immediate
implications for patients treated with this regimen.
Our data suggest that the combination of cisplatin at 80
mg/m2 IV with weekly docetaxel (35 mg/m2) IV or docetaxel
(75 mg/m2) IV every 3 weeks is no better tolerated than
chemotherapy regimens used in IALT. The most common
reason to stop postoperative cisplatin and docetaxel was
intolerable fatigue, which most often occurred after the first
cycle. Neutropenia was seldom an issue in early discontinu-
ation of therapy on either schedule. The every 3 weeks
docetaxel plus cisplatin regimen is more amenable to the
routine use of filgrastim, or pegylated filgrastim, to prevent
neutropenia compared with weekly chemotherapy regimens.
In this study, only four of 11 patients on the every 3 weeks
cohort (36%) required treatment with pegylated filgrastim.
Eleven of 27 patients treated in either cohort (41%) required
treatment with darbepoetin. Despite using state-of-the-art
acute and delayed emesis prophylaxis, seven patients (26%)
experienced grade 3–4 nausea, and it was dose limiting in six
patients. This is not unexpected, as the addition of aprepitant
to standard antiemetics had little effect on the prevention of
nausea in randomized trials.31,32
In this study, fatigue was the dose-limiting toxicity in
eight of 11 patients who dropped out early, and 30% of all
patients treated experienced grade 3–4 fatigue. The published
adjuvant trials report rates of grade 3–4 fatigue as high as
28% using high-dose cisplatin with vinorelbine.3 In patients
with metastatic NSCLC treated with cisplatin plus docetaxel
or vinorelbine, grade 3–4 fatigue was reported in only 12% to
14% of patients.9,10 Clearly, patients immediately postopera-
tively are more susceptible to fatigue from cisplatin-based
chemotherapy than patients with metastatic NSCLC.
Of note, grade 3–4 fatigue occurred less frequently in
the BR10 trial (compared with ANITA) in which cisplatin
was administered as a split dose with 50 mg/m2 IV given on
days 1 and 8 of each monthly cycle, with weekly vinorelbine.
Despite lower rates of fatigue and nausea with this approach,
similar proportions of patients completed one, two, three,
and four cycles of chemotherapy in ANITA and BR10. Our
trial did not explore whether split-dose cisplatin might
mitigate fatigue or improve drug delivery in combination
with docetaxel.
Based on our phase II data and the phase III adjuvant
data using cisplatin plus vinorelbine, it is anticipated that
approximately one half of patients will be unable to receive
all four planned chemotherapy cycles in the intergroup adju-
vant study (ECOG 1505). Treatment with split-dose cisplatin
is not an option in ECOG 1505. Drug delivery will likely be
even lower in the experimental arm of the study as the
coadministration of bevacizumab will lead to increased tox-
icity, particularly neutropenia, hypertension, venous and ar-
terial thrombotic events, and toxic deaths.
In conclusion, docetaxel plus cisplatin was difficult to
deliver in the postoperative setting in this phase II trial. The
most common dose-limiting toxicities are more likely attrib-
utable to cisplatin rather than the docetaxel, given that the
same problems were encountered whether the docetaxel was
delivered at a single high or lower weekly dose. These results
predict difficulty in delivering cisplatin and docetaxel in both
the control and experimental treatment arms of ECOG 1505.
The results of ongoing randomized trials comparing preop-
erative versus postoperative delivery of docetaxel/cisplatin
will be of significant interest. Priority should be given to
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developing noncisplatin adjuvant regimens for evaluation in a
phase III trial.
The therapeutic benefit of adjuvant chemotherapy
should be enhanced through identification of more efficacious
regimens and alternatives to cisplatin-based therapy. As dem-
onstrated in this study, many patients prove intolerant to
cisplatin and cannot complete prescribed therapy. Others are
not candidates for cisplatin due to comorbid medical illness.
In the future, the development of better prognostic molecular
tests will allow low-risk patients to be spared adjuvant ther-
apy,23 and better predictive molecular tests may allow mo-
lecularly tailored adjuvant therapies. Recent research has
identified subpopulations of patients who are inherently re-
sistant to cisplatin-based chemotherapy. For example, over-
expression of the DNA repair protein ERCC1 (excision repair
cross-complementation group 1) in the resected tumor pre-
dicted a lack of benefit from adjuvant cisplatin, theoretically
due to de novo resistance of the cancer to cisplatin-induced
DNA damage.33 Selection of noncisplatin regimens for these
patients may improve outcome, and a phase II tolerability
study of vinorelbine plus docetaxel in ERCC1-positive pa-
tients is planned for possible evaluation in a phase III trial.
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